MAP2K7 and cutaneous melanoma: A recently published retrospective study demonstrated the clinical efficacy and safety of a combination therapy consisting of BRAF and MEK inhibitors (dabrafenib plus trametinib) in Japanese patients with unresectable or metastatic BRAF V600-mutant cutaneous melanoma (27).